Table 6.

Target‐Specific Anticoagulants Approved for Use

Indication	Dabigatran	Rivaroxaban	Apixaban
Stroke prevention in AF	150 mg twice daily	20 mg once daily	5 mg twice daily
Acute VTE treatment	Not approved	20 mg once daily	Not approved
VTE prevention in TKA or THA	220 mg once daily*	10 mg once daily	2.5 mg twice daily*

AF indicates atrial fibrillation; THA, total hip arthroplasty; TKA, total knee arthroplasty; VTE, venous thromboembolism.

^*Only approved in Europe and Canada for this indication.